Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.43 |
| ▸ | RBP4 | P02753 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006514 | 0.88 | DPP4 (0.50) | DPP4DPP8DPP9DPP7RBP4 | |
| SCHEMBL14970433 | 0.87 | RBP4 (0.53) | DPP4DPP8DPP9DPP7RBP4 | |
| SCHEMBL23881432 | 0.86 | DPP4 (0.40) | DPP4DPP8DPP9DPP7P2RX7 | |
| SCHEMBL19124072 | 0.83 | DPP4 (0.54) | DPP4DPP8DPP9DPP7P2RX7 | |
| SCHEMBL1424003 | 0.81 | DPP4 (0.46) | DPP4DPP8DPP9DPP7P2RX7 | |
| SCHEMBL17317780 | 0.78 | DPP4 (0.47) | DPP4DPP8DPP9DPP7P2RX7 | |
| SCHEMBL5645375 | 0.77 | DPP4 (0.52) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL28646727 | 0.77 | P2RX7 (0.39) | DPP4DPP8DPP9DPP7P2RX7 | |
| SCHEMBL28644919 | 0.77 | CREBBP (0.41) | P2RX7RBP4 | |
| SCHEMBL17317850 | 0.77 | P2RX7 (0.39) | P2RX7RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152206-A1 | ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.